{"title":"[Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5<sup>+</sup> Diffuse Large B-Cell Lymphoma].","authors":"Ya-Ping Wang, Xue-Ya Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2024.04.021","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics and treatment of relapsed CD5<sup>+</sup> diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>The data of a patient with CD5<sup>+</sup> DLBCL was collected, and its clinical characteristics and treatment outcome were analyzed.</p><p><strong>Results: </strong>The patient developed hemophagocytic syndrome and achieved complete remission (CR) after 6 cycles of R-ECHOP chemotherapy, then relapsed. After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment, the patient achieved CR again accompanied by a decrease of interleukin (IL)-10 expression level. After a total of 15 cycles of chemotherapy, the patient remained in CR for 24 months, and the level of IL-10 remained in the normal range.</p><p><strong>Conclusion: </strong>PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5<sup>+</sup> DLBCL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"32 4","pages":"1112-1116"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the clinical characteristics and treatment of relapsed CD5+ diffuse large B-cell lymphoma (DLBCL).
Methods: The data of a patient with CD5+ DLBCL was collected, and its clinical characteristics and treatment outcome were analyzed.
Results: The patient developed hemophagocytic syndrome and achieved complete remission (CR) after 6 cycles of R-ECHOP chemotherapy, then relapsed. After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment, the patient achieved CR again accompanied by a decrease of interleukin (IL)-10 expression level. After a total of 15 cycles of chemotherapy, the patient remained in CR for 24 months, and the level of IL-10 remained in the normal range.
Conclusion: PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5+ DLBCL.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
